Preoperative Bevacizumab for Vitreous Hemorrhage

Intra-Operative and Postoperative Intraocular Bleeding After Pars Plana Vitrectomy for Vitreous Hemorrhage in Diabetic Patients Previously Treated With Intravitreal Bevacizumab

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00596297

Acronym

IBEVI

Enrollment

Registered

2008-01-16

Start date

2007-11-30

Completion date

2008-09-30

Last updated

2008-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy, Vitreous Hemorrhage

Keywords

Diabetic Retinopathy, Vitreous Hemorrhage, Bevacizumab, pars plana vitrectomy, preoperative

Brief summary

The purpose of this study is to determine whether preoperative intravitreal bevacizumab is effective in reducing intra-operative and postoperative bleeding in diabetic patients submitted to pars plana vitrectomy for vitreous hemorrhage.

Interventions

DRUGbevacizumab

Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline

PROCEDUREpars plana vitrectomy

4 weeks after baseline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diabetic retinopathy causing significant vitreous hemorrhage with visual acuity loss lasting more than three months in patients not previously treated and four months in those previously LASER treated.

Exclusion criteria

* Previous intra-ocular surgery other than cataract surgery * Retinal detachment * Use of anticoagulants drugs other than aspirin * Vitreous hemorrhage clearance at week-3 study period * History of previous thromboembolic events

Design outcomes

Primary

Measure	Time frame
Intra- and postoperative intra-ocular bleeding	12 weeks

Secondary

Measure	Time frame
Visual acuity	12 weeks

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026